(MENAFN- PR Newswire)
RADNOR, Pa., June 7, 2022 /PRNewswire/ — NRx Prescription drugs, Inc. (Nasdaq: NRXP ), a clinical-phase biopharmaceutical corporation, declared right now that the firm’s Board of Directors appointed Seth Van Voorhees, Ph.D. as Chief Money Officer and Treasurer effective June 13, 2022.
Seth Van Voorhees
‘Dr. Van Voorhees is a really achieved CFO with in depth encounter in company finance, capital marketplaces, financial investment banking and licensing. His appointment arrives at an vital time for our Corporation, as we are concentrating our methods principally on our psychiatry franchise. His economical and scientific expertise will be instrumental in aiding us to continue to mature the Company,’ reported Robert Besthof, Interim Main Govt Officer of NRx Prescribed drugs. ‘We are grateful to Ira Strassberg for his important contributions to the Firm since last August, including the establishment of sturdy internal controls and the additional construct-up of our finance and accounting function at the Company.’
‘I am happy to sign up for NRx Prescription drugs at this fascinating phase, as the Corporation is focusing principally on the development of NRX-101, its Breakthrough Designation Treatment for Critical Bipolar Despair in patients with Acute Suicidal Ideation and Actions (ASIB). Its scientific system results in interesting chances to tackle the incredibly large unmet want of treating bipolar melancholy in clients with suicidality, as nicely as other psychiatric ailments. Up to 50% of men and women with bipolar disorder endeavor suicide around their life time, and clients with bipolar depression and suicidality have ordinarily been excluded from clinical scientific studies. The Firm is presently enrolling patients in a Period II trial studying sufferers with bipolar despair and sub-acute suicidality (not necessitating hospitalization) and plans to initiate a Section IIb/III registrational trial in patients with bipolar depression and ASIB (requiring hospitalization) later on this calendar year,’ explained Dr. Van Voorhees.
Dr. Van Voorhees most recently served as CFO of PDS Biotechnology through which he concluded many funding transactions in 2021. Prior to signing up for PDS Biotechnology, he invested 10 several years as the CFO for Exploration Frontiers and for American Pacific. Previously in his career, Dr. Van Voorhees labored in expense banking supporting chemical/pharmaceutical clients at Merrill Lynch, UBS Warburg, and Wasserstein Perella. He received a Ph.D. in chemistry from the College of Pennsylvania and an MBA from Columbia University.
About NRx Pharmaceuticals
NRx Prescription drugs, Inc. (‘NRx Pharmaceuticals’ or the ‘Company’) attracts on many years of collective, scientific, and drug-growth knowledge to deal with pretty superior unmet needs of individuals and provide improved wellness to sufferers. The U.S. Food and Drug Administration (‘FDA’) has on top of that granted Breakthrough Therapy designation, a Unique Protocol Agreement, and a Biomarker Letter of Assistance for NRX-101, an investigational drugs for the procedure of extreme bipolar despair in individuals with acute suicidal ideation and conduct (ASIB) following first stabilization with ketamine or other effective therapy. NRx Prescribed drugs is led by executives who have held leadership roles at Lilly, Pfizer, and Novartis as nicely as main expenditure banking establishments.
Cautionary Notice Regarding Forward-Seeking Statements
This announcement of NRx Prescribed drugs, Inc. contains ‘forward-searching statements’ within the which means of the ‘safe harbor’ provisions of the U.S. Personal Securities Litigation Reform Act of 1995, which may possibly consist of, but are not restricted to, statements pertaining to our fiscal outlook, product or service improvement, small business prospects, and sector and field trends and situations, as well as the Company’s tactics, options, aims, and aims. These forward-hunting statements are dependent on present-day beliefs, anticipations, estimates, forecasts, and projections of, as effectively as assumptions manufactured by, and info at present accessible to, the Firm’s administration.
The Business assumes no obligation to revise any ahead-wanting assertion, no matter whether as a result of new data, potential activities or otherwise. Appropriately, you should not area reliance on any forward-looking statement, and all forward-seeking statements are herein skilled by reference to the cautionary statements set forth above.
Corporate Make contact with Molly CoganSr. Director, World wide Communications [email protected]
Trader RELATIONS Tim McCarthyInvestor Relations[email protected]
Source NRx Prescription drugs, Inc.
Lawful Disclaimer: MENAFN presents the details “as is” with no warranty of any kind. We do not accept any obligation or liability for the precision, information, illustrations or photos, video clips, licenses, completeness, legality, or reliability of the facts contained in this short article. If you have any problems or copyright difficulties related to this short article, kindly get in touch with the supplier earlier mentioned.